New Delhi, Mar 27 (PTI) Zydus Lifesciences on Wednesday said the US health regulator has issued a Form-483 with four observations following the inspection of its Ahmedabad-based SEZ Onco Injectable manufacturing plant.

The US Food and Drug Administration (USFDA) conducted the cGMP (Current Good Manufacturing Practice) inspection at the facility from March 18-27, 2024, the company said in a regulatory filing.

Also Read | Francis Scott Key Bridge Collapse in Baltimore: Things to Know About Key Bridge aka Beltway Bridge in the US That Collapsed Into River After Being Struck by Cargo Ship.

The inspection closed with four observations, it added.

There were no data integrity-related observations, the drug firm said.

Also Read | Shaheed Diwas 2024 Date in India: Know History and Significance of the Day That Commemorates Death Anniversary of Bhagat Singh, Sukhdev and Rajguru.

Zydus will closely work with the USFDA to address the observations, it added.

Shares of the company ended 1.82 per cent lower at Rs 999.60 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)